Paliperidone

帕利哌酮

Report date: 2024/06/27 17:11:48
NME

Base Information

Drug NamePaliperidone
Drug Alias Name帕立派酮Paliperidona帕潘立酮Paliperidonum帕立哌酮 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsSchizoaffective disorderSchizophreniaPsychotic Disorders +[10] 
Global Approved IndicationsSchizophrenia
Approved Indications in ChinaSchizophrenia
Original Approved Country/TerritoryUnited States
Original Approved Date2006/12/19
Country/TerritoryBelgiumBulgariaPanama +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineJanssen-Cilag International NvJanssen, Lp +[4] 
Inactive CompaniesJanssen Pharmaceutica SaXian Janssen Pharmaceutical LtdOrtho-Mcneil Janssen Scientific Affairs Llc +[9] 
Active IndicationsSchizoaffective disorderSchizophrenia
Inactive IndicationsPsychotic DisordersAutistic DisorderMood Disorders +[8] 

Other Information

ATC CodeN05AX13
Related LinksWikipediaDrugBankKEGG